Dian Wang, MD, PhD - Rush University ...

Dr. Dian Wang, MD, PhD

Claim this profile

Rush University Medical Center

Studies Prostate Cancer
Studies Prostate Adenocarcinoma
14 reported clinical trials
39 drugs studied

Area of expertise

1

Prostate Cancer

Dian Wang, MD, PhD has run 7 trials for Prostate Cancer. Some of their research focus areas include:

Stage I
Stage II
2

Prostate Adenocarcinoma

Dian Wang, MD, PhD has run 5 trials for Prostate Adenocarcinoma.

Affiliated Hospitals

Image of trial facility.

Rush University Medical Center

Image of trial facility.

Rush University Cancer Center

Clinical Trials Dian Wang, MD, PhD is currently running

Image of trial facility.

Brachytherapy

for Pancreatic Cancer

Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.

Recruiting

1 award

Phase 1 & 2

12 criteria

Image of trial facility.

Apalutamide + Targeted Radiation

for Prostate Cancer

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.

Recruiting

2 awards

Phase 3

More about Dian Wang, MD, PhD

Clinical Trial Related

8 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Dian Wang, MD, PhD has experience with

  • Radiation Therapy
  • Bicalutamide
  • Flutamide
  • Docetaxel
  • Apalutamide
  • Degarelix

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Dian Wang, MD, PhD specialize in?

Is Dian Wang, MD, PhD currently recruiting for clinical trials?

Are there any treatments that Dian Wang, MD, PhD has studied deeply?

What is the best way to schedule an appointment with Dian Wang, MD, PhD?

What is the office address of Dian Wang, MD, PhD?

Is there any support for travel costs?